Regeneron-anti-ebola antibody therapeutics program development
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSO100201500013C
- Awardee
-
Regeneron Pharmaceuticals Inc. UEI N3F9MH7E6HD6
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- BAA13100SOL00013 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $44,440,563.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
About this IDV
This single-award Indefinite Delivery Contract was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services, to Regeneron Pharmaceuticals Inc. on September 2, 2015, with an ultimate completion date of September 30, 2023. The contract, valued at $44.4 million with no set-aside provisions, supports the Regeneron Anti-Ebola Antibody Therapeutics Program Development. The primary scope encompasses the development and production of monoclonal antibody therapeutics designed to treat Ebola virus disease, representing a critical component of the federal government's biodefense and pandemic preparedness capabilities. Regeneron's established expertise in recombinant antibody technology and large-scale therapeutic manufacturing positioned the company as the prime contractor for this specialized medical countermeasure initiative.
Under this IDV vehicle, Regeneron was tasked with advancing anti-Ebola therapeutic candidates through development phases while maintaining production readiness for potential emergency deployment. This contract reflects the federal government's strategic investment in medical countermeasures for high-consequence infectious diseases and represents part of broader preparedness efforts coordinated through ASPR. The contract includes a de-obligation of fiscal year 2024 funds, indicating modifications to funding levels during its performance period. As a leading pharmaceutical manufacturer with established government relationships across the Department of Defense, Department of Veterans Affairs, and HHS, Regeneron has demonstrated capability in scaling therapeutic production to meet national health security requirements, as evidenced by subsequent large-scale manufacturing initiatives during the COVID-19 pandemic.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,435,528 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $15,085,061 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $2,417,509 | |
| Original award | $17,068,518 |
Show all 12
Quick answers
Who was awarded contract HHSO100201500013C?
HHSO100201500013C was awarded to Regeneron Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 2, 2015.
How much is contract HHSO100201500013C worth?
HHSO100201500013C's own ceiling is $44,440,563.
Who can order from contract HHSO100201500013C?
HHSO100201500013C is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSO100201500013C competed?
The extent of competition for HHSO100201500013C was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV